<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/053FB3C6-5CB3-47DA-9A7A-908B6E0E9B7F"><gtr:id>053FB3C6-5CB3-47DA-9A7A-908B6E0E9B7F</gtr:id><gtr:firstName>Joanne</gtr:firstName><gtr:otherNames>Louise</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/29617405-8FC1-49EC-A600-3D1C5032A458"><gtr:id>29617405-8FC1-49EC-A600-3D1C5032A458</gtr:id><gtr:firstName>Alasdair</gtr:firstName><gtr:surname>Coles</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100114"><gtr:id>6A6C4EDD-9976-490A-A32C-EAC3C8F627AF</gtr:id><gtr:title>Developmental Clinical Studies - new use of a licensed drug in preventing autoimmunity after alemtuzumab treatment of MS</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100114</gtr:grantReference><gtr:abstractText>Multiple sclerosis (MS) is an autoimmune disease in which the patients? own immune system attacks their brain and spinal cord causing damage. It is the most common cause of disability in young adults in the western world.
Alemtuzumab is the most effective drug treatment of multiple sclerosis tested to date; not only does it prevent new attacks, it also improves disability. Alemtuzumab works by binding to and killing lymphocytes, cells which normally fight infections but which mistakenly attack nerves in multiple sclerosis. Although effective, alemtuzumab has side effects, in particular, 1 in 3 patients develop a new autoimmune disease after treatment. In other words, as their immune system grows back it begins to attack other parts of their body, most commonly the thyroid gland. 
We believe that these autoimmune diseases occur because of the way the immune system grows back after alemtuzumab: by expanding up the small pool of lymphocytes not depleted by alemtuzumab. We propose to get round this by giving a drug which boosts the thymus gland to produce new lymphocytes. We will treat 42 MS patients with alemtuzumab; half will also receive a licensed drug that boosts the thymus and half will be given a placebo. Our final measure of the success of our approach will be the proportion of patients in each group who go to develop an autoimmune disease after alemtuzumab. But, one year into the trial, we will have a ?stop-go? point where we measure the activity of the thymus in our patients; if the trial drug does not seem to be boosting the thymus we will stop the trial early.
Our work is important - enabling patients to receive alemtuzumab without the risk of developing autoimmunity would represent a huge step forward in the management of multiple sclerosis. Furthermore this trial tests a general strategy for encouraging the recovery of the immune system in humans, and as such, has implications for people with HIV or those recovering from chemotherapy.</gtr:abstractText><gtr:technicalSummary>We propose to test the efficacy of a licensed drug to prevent autoimmunity caused by reconstitution following lymphocyte depletion. The specific context of this trial is autoimmunity after alemtuzumab (formerly ?Campath-1H?) treatment of multiple sclerosis, but positive results would have implications for many clinical contexts. Alemtuzumab is arguably the most effective treatment of multiple sclerosis to date; if autoimmunity, its most significant adverse effect, could be minimised then many more people would benefit from this efficacy.
Multiple sclerosis is the most common cause of disability in young adults in the Western world, effecting 100,000 people in the United Kingdom. Treatments to date have been only partially effective. Alemtuzumab is a lymphocyte-depleting humanised anti-CD52 monoclonal antibody, investigated by us as a treatment of multiple sclerosis since 1991; it is a rare example of academic-led translational medicine. Our phase 2 results of treatment of early relapsing-remitting multiple sclerosis demonstrate greater efficacy of alemtuzumab, compared to standard licensed therapy (interferon-beta1a), than any other treatment of multiple sclerosis. An unprecedented result was that that disability of patients five years after alemtuzumab was improved from baseline. Phase 3 trials of alemtuzumab will complete by Q42011 and submissions for licensing will be in Q32012. 
T-cell reconstitution after alemtuzumab occurs by expansion of peripheral T-cells that have escaped depletion, rather than by the generation of new T-cells via the thymus. This results in a population of T-cells that are restricted in diversity and skewed towards auto-reactivity. It is likely that these cells cause the main adverse effect of alemtuzumab, namely autoimmunity months to years after treatment (30% of patients develop thyroid autoimmunity and 3% idiopathic thrombocytopenic purpura); this risk is increased in patients with high serum IL-21. 
The hypothesis underlying this trial is that autoimmunity after alemtuzumab will be reduced if this peripheral T-cell expansion is suppressed by increasing thymic production of naive T-cells. Our investigational drug has these effects in a variety of animal models. It is licensed for use in humans (for a different indication) and is well tolerated. To date no-one has investigated its effect on thymic reconstitution in humans. So, we propose a double-blind randomised (1:1) placebo-controlled trial of our investigational agent in 42 patients treated with alemtuzumab for relapsing remitting multiple sclerosis who are at high-risk of developing. The primary outcome measure will be the development of secondary autoimmunity following treatment.</gtr:technicalSummary><gtr:fund><gtr:end>2017-11-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>965058</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Linda Wicker and John Todd</gtr:description><gtr:id>650D25B5-8900-496F-BC84-C51A2E7F1A2A</gtr:id><gtr:impact>Nil to date
One manuscript in preparation</gtr:impact><gtr:partnerContribution>Linda Wicker provides novel intellectual insights into her project.
Sarah Howlett has undertaken the mouse work critical to udnerstanding the paradoxical effect of palifermin</gtr:partnerContribution><gtr:piContribution>JohnTodd's group has moved from Cambridge to Oxford
Linda Wicker has become a close collaborator, participating weekly in lab meetings.
One of her group members (Sarah Howlett) has moved to my group.
Two of her group members are working physically in my group, but administatively remain under the Oxford Todd/Wicker supervision.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge Multiple Sclerosis Research Open Day 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>51975416-5E2F-432F-89FB-EBF6041DA7D5</gtr:id><gtr:impact>100 people with MS and their carers heard presentations from my research team, and others in Cambridge doing research on MS about their current research.

Increased recruitment to trials in Camrbidge</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Multiple Sclerosis Research Open Day 2014</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1ACA7776-7A44-47B9-A7B5-E9F432B6BF45</gtr:id><gtr:impact>A morning of presentations from post-docs in groups undertaking MS -related research in Camrbidge followed by a Q&amp;amp;A panel.
I designed the day, invited the speakers and chaired the sessions.
200 people attended
Administered by a local MS Soc brainch

Widespread positive feedack</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival Cambridge 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>57201862-9FDD-4161-937F-A266174E8734</gtr:id><gtr:impact>A panel of 6 people discussed the scientific, clinical, patient and regulatory perspectives on the development of Campath-1H as a treatment for multiple sclerosis, including the CAMTHY trial.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Biomedical Research Centre Open Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>609C47FB-5E28-4DD2-905A-81A9149526D4</gtr:id><gtr:impact>1 hour talk and Q&amp;amp;A on our research in multiple sclerosis</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Expert Adviser at NICE appraisal of alemtuzumab treatment of MS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6CD54E25-2510-451C-B618-D7085B05CC48</gtr:id><gtr:impact>A new drug has been licensed for the treatment of MS</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair and principal author of NHS ENgland's 2017 algorithm on the use of disease modifying therapies in multiple sclerosis</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1AB6EDAA-4FB3-4AAE-AFB0-87177FEDD797</gtr:id><gtr:impact>The NHS England DMT algorithm increases access of people with multiple sclerosis to disease-modifying therapies and promotes good practice across the UK.</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have been investigating a novel repurposing of palifermin: to promote thymic T cell production.
The specific context of this trial was to promote lymphocyte production after alemtuzumab treatment of multiple sclerosis.
As of Jan 2016, further dosing of palifermin was stopped in this trial, as it appeared to have a paradoxical effect of reducing thymic output.</gtr:description><gtr:id>185E8D54-8502-46F9-B169-3F77C4F42D96</gtr:id><gtr:impact>We will be disseminating this negative trial result to prevent others using palifermin to promote thymic lymphocyte production.</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Palifermin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15AB2B62-3484-45C2-B71D-89351B995BDE"><gtr:id>15AB2B62-3484-45C2-B71D-89351B995BDE</gtr:id><gtr:title>Immune competence after alemtuzumab treatment of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f39be260aa5a0ad344532f0da8899c66"><gtr:id>f39be260aa5a0ad344532f0da8899c66</gtr:id><gtr:otherNames>McCarthy CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23731C88-4F2C-4609-99E6-448D9597CBEF"><gtr:id>23731C88-4F2C-4609-99E6-448D9597CBEF</gtr:id><gtr:title>Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97f12f5d358943ad062bbeee1f735874"><gtr:id>97f12f5d358943ad062bbeee1f735874</gtr:id><gtr:otherNames>Hill-Cawthorne GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA275B53-18D5-463B-B809-C81839651D88"><gtr:id>CA275B53-18D5-463B-B809-C81839651D88</gtr:id><gtr:title>Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2514c8bd7319d355347e4a4e3112978a"><gtr:id>2514c8bd7319d355347e4a4e3112978a</gtr:id><gtr:otherNames>Jones JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/991CE544-624C-4C40-BC78-B5DC1CA4426B"><gtr:id>991CE544-624C-4C40-BC78-B5DC1CA4426B</gtr:id><gtr:title>Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4f6c936508879a7809e152ba675c9e43"><gtr:id>4f6c936508879a7809e152ba675c9e43</gtr:id><gtr:otherNames>Abrahamsson SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B5A71CBE-BFBC-4C2F-9A82-37A3217F5FD1"><gtr:id>B5A71CBE-BFBC-4C2F-9A82-37A3217F5FD1</gtr:id><gtr:title>Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Expert review of neurotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f72cc0077fb17a29ee69e897fbdd5c1f"><gtr:id>f72cc0077fb17a29ee69e897fbdd5c1f</gtr:id><gtr:otherNames>Costelloe L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7175</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/76AC01D3-D5D2-4EDB-9983-1D7AAAD57770"><gtr:id>76AC01D3-D5D2-4EDB-9983-1D7AAAD57770</gtr:id><gtr:title>Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1c3a98f7a384ad45976b14e02b9e83b"><gtr:id>b1c3a98f7a384ad45976b14e02b9e83b</gtr:id><gtr:otherNames>Kousin-Ezewu O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D009E3D6-256D-45CB-A2F9-F0524C5F988B"><gtr:id>D009E3D6-256D-45CB-A2F9-F0524C5F988B</gtr:id><gtr:title>Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90597236631e7779671085b6a248dddc"><gtr:id>90597236631e7779671085b6a248dddc</gtr:id><gtr:otherNames>Tuohy O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FF7A03C-32D6-4645-A7CC-50EAFBFCC4BD"><gtr:id>9FF7A03C-32D6-4645-A7CC-50EAFBFCC4BD</gtr:id><gtr:title>Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04643f2148920ad18ad1258e49081cce"><gtr:id>04643f2148920ad18ad1258e49081cce</gtr:id><gtr:otherNames>Azzopardi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100114</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>